ABSTRACT
Rare genetic variants have been previously associated with amyotrophic lateral sclerosis (ALS). In a large multi-ethnic cohort of 6,970 ALS patients, rare variant burden testing validated known ALS genes and demonstrated the utility of intolerant domain-based collapsing methods. A first- ever analysis in 166 patients with primary lateral sclerosis (PLS), a motor neuron disease related to ALS, found a candidate association to loss-of-function mutations in ANTXR2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The collection of ALS samples and data was funded in part by: The Scottish Genomes Partnership (Chief Scientist Office of the Scottish Government Health Directorates (SGP 1) and The Medical Research Council Whole Genome Sequencing for Health and Wealth Initiative (MC PC 15080); The New York Genome Center ALS Consortium (ALS Association 15 LGCA 234, 19 SI 459, and the Tow Foundation; The GTAC study (ALS Association 16 LGCA 310 and Biogen Idec); ALS Exome Sequencing Consortium (Biogen Idec).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All samples and data came from participants that provided written, informed consent for genetic studies that had been IRB-approved at each contributing center. The study cohort includes participants from the Genomic Translation for ALS Care (GTAC study), the Columbia University Precision Medicine Initiative for ALS, the New York Genome Consortium, and the ALS Sequencing Consortium (IRB-approved genetic studies from Columbia University Medical Center, including the Coriell NINDS repository), University of Massachusetts at Worchester, Stanford University (including samples from Emory University School of Medicine, the Johns Hopkins University School of Medicine, and the University of California, San Diego), Massachusetts General Hospital Neurogenetics DNA Diagnostic Lab Repository, Duke University, McGill University (including contributions from Saint-Luc and Notre-Dame Hospital of the Centre Hospitalier de lUniversite de Montreal [CHUM], [University of Montreal]), Gui de Chauliac Hospital of the CHU de Montpellier (Montpellier University), Pitie Salpetriere Hospital, Fleurimont Hospital of the Centre Hospitalier Universitaire de Sherbrooke (CHUS) (University of Sherbrooke), Enfant Jesus Hospital of the Centre hospitalier affilie universitaire de Quebec (CHA) (Laval University), Montreal General Hospital, Montreal Neurological Institute and Hospital of the McGill University Health Centre, the University of Edinburgh Scotland, and Washington University in St. Louis (including contributions from Houston Methodist Hospital, Virginia Mason Medical Center, University of Utah, and Cedars Sinai Medical Center).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All summary data produced in the present work are contained in the manuscript
